Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Revance Therapeutics, Inc.
Develops both topical and longer lasting injectable formulations of Botox
Transaction Summary
Completed a $110M IPO and $140M secondary in 2014 to fund clinical trials for both products
Moving forward on clinical trials in four separate indications for both topical and injectable
Released positive Phase II data on 6 month duration of RT002, the company's long lasting injectable
Newark, CA
NASDAQ: RVNC
Contact:
Ron Eastman
www.revance.com
Formerly Known As: Essentia BioSystems Inc.
IPO
Exit date: February 06, 2014
Related News
Revance Announces $45M Financing
Revance Announces Positive Results in RT002 Injectable Phase 2 Cervical Dystonia Trial
Revance Appoints Mark Foley to its Board of Directors
Revance Reports Positive Six-Month Duration in BELMONT Study